Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Verve Therapeutics Inc
(NQ:
VERV
)
6.350
+0.380 (+6.37%)
Streaming Delayed Price
Updated: 10:04 AM EDT, Oct 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Verve Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Verve Therapeutics to Participate in Upcoming Investor Conferences
May 30, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Cathie Wood's Ark Innovation ETF Sees Sharp Decline Among Top Holdings — Here Are 10-Largest Losers Within ARKF
May 28, 2024
Cathie Wood's flagship ARK Innovation ETF has been navigating through significant losses, showcasing the challenges faced by some of its major holdings.
Via
Benzinga
Topics
ETFs
Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024
May 17, 2024
Discover three biotech stocks handpicked by Cathie Wood, offering groundbreaking therapies and substantial growth potential.
Via
InvestorPlace
3 Underappreciated Stocks That Could 10x in 10 Years
May 12, 2024
10x stocks are the holy grail of capital investing. So, here are three companies that have the potential to cross that line.
Via
InvestorPlace
After a Serious Setback, Is Verve Therapeutics a Buy?
April 06, 2024
There are a few silver linings at play here.
Via
The Motley Fool
Verve Therapeutics: Q4 Earnings Insights
February 27, 2024
Via
Benzinga
VERV Stock Earnings: Verve Therapeutics Beats EPS, Beats Revenue for Q1 2024
May 08, 2024
VERV stock results show that Verve Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results
May 08, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102
May 07, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 03, 2024
From
Verve Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
April 23, 2024
Via
Benzinga
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter
April 11, 2024
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Via
Benzinga
Cathie Wood's Ark Invest Sheds $6.4M Worth Of Coinbase Shares Despite Positive Market Movements, Analyst Upgrade
April 04, 2024
On Thursday, Cathie Wood-led Ark Invest made a significant move by selling shares of Coinbase Global Inc (NASDAQ:COIN), despite the stock’s positive market performance on the same day. The COIN Trade
Via
Benzinga
Cathie Wood's Ark Invest Buys More Shares Of This Meta Platforms Competitor
April 03, 2024
Via
Benzinga
Nasdaq Down Over 1%; VivoPower International Shares Spike Higher
April 02, 2024
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dipping over 1% on Tuesday. The Dow traded down 1.07% to 39,142.53 while the NASDAQ fell 1.14% to 16,209.12. The S&P 500...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Dow Stumbles, Heads For Worst Day Since February
April 02, 2024
Stocks are starting the second quarter off on the wrong foot, as profit taking grips Wall Street.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Why Stryve Foods Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
April 02, 2024
Shares of Stryve Foods, Inc. (NASDAQ: SNAX) fell sharply during Tuesday’s session following a fourth-quarter revenue miss.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
April 02, 2024
Via
Benzinga
Gene Therapy Side Effects: Verve Therapeutics Halts Enrollment Of Lead Gene Therapy Trial In Patients With Bad Cholesterol
April 02, 2024
Verve Therapeutics' latest update on the Heart-1 Phase 1b trial of VERVE-101. Explore VERVE-102's development and regulatory clearances for the Heart-2 clinical trial, offering hope for patients with...
Via
Benzinga
Crude Oil Surges Over 1%; US Factory Orders Increase In February
April 02, 2024
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 1% on Tuesday. The Dow traded down 1.05% to 39,152.47 while the NASDAQ fell 1.17% to 16,205.37. The S&P 500...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
April 02, 2024
From
Schall Law
Via
GlobeNewswire
Verve Plummets To Record Low After Its Gene-Editing Drug Causes Side Effects
April 02, 2024
The company is now pausing enrollment in the study of its lead asset, VERVE-101.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
April 02, 2024
Via
Benzinga
Verve Therapeutics Announces Updates on its PCSK9 Program
April 02, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 28, 2024
From
Verve Therapeutics
Via
GlobeNewswire
3 Stocks That Could Be the Next Big Thing in Gene Editing
March 21, 2024
Gene editing could revolutionize how millions of patients are treated. That could create big opportunities for gene-editing stocks.
Via
InvestorPlace
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 01, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Beam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug
February 27, 2024
Both companies are working on treatments for genetic disorders.
Via
Investor's Business Daily
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024
From
Verve Therapeutics
Via
GlobeNewswire
3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough Potential
February 19, 2024
Biotech stocks, namely those involved with gene editing, have been explosive and could see higher highs with strong catalysts.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.